Abstracts tagged "Infection"

Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 0204 • ACR Convergence 2021
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Soo Min Ahn¹, Jonggi Choi², Byong Duk Ye², Suk-Kyun Yang², Ji Seon Oh³, Yong-Gil Kim², Chang-Keun Lee², Bin Yoo¹, Sang Hyoung Park² and Seokchan Hong², ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0264 • ACR Convergence 2020
Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
Nouf Alhammadi¹, Murray Urowitz² and Dafna Gladman³, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a…
Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Bonnia Liu¹, Victor Yang², Christopher McMaster³, Russell Buchanan⁴, Albert Frauman⁵ and David Liew⁶, ¹Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, ²Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ⁶Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
Abstract Number: 1620 • ACR Convergence 2020
Hepatitis B Screening Practices When Prescribing Tocilizumab or Tofacitinib in Real World Practice
Naomi Serling-Boyd¹, Amir Mohareb², Arthur Kim², Emily Hyle² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Hepatitis B virus (HBV) reactivation can complicate treatment with immunosuppressive medications. Reactivation risk varies by the status of HBV infection but has been reported…
Abstract Number: 0430 • ACR Convergence 2020
Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
Kristin D'Silva¹, April Jorge¹, Na Lu², Yuqing Zhang³, Zachary Wallace⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 1623 • ACR Convergence 2020
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Bonnie Bermas², Puneet Bajaj³, Nagendra Pokala¹, Reuben Arasaratnam⁴, Joan Reisch¹ and Dan (Clarie) Wang¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UTSouthwestern.edu, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are particularly vulnerable to pneumococcal infection due to both their underlying disease and immunosuppressive therapy. Thus, quality improvement metrics include increasing pneumococcal…
Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Tiphaine Lenfant¹, Elizabeth Kirchner², Rula Hajj-ali³, Leonard Calabrese³ and Cassandra Calabrese³, ¹Cleveland Clinic Foundation, Rocky River, OH, ²Cleveland Clinic Foundation, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Zahra Rehman¹, Megan Krause¹, Jessica Newman² and Pooja Bhadbhade¹, ¹The University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].